{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:30:24Z","timestamp":1792668624873,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Evidence suggests that infusional therapy is a more effective means for administering cytotoxic therapy than intravenous bolus therapy for lymphoma and offers greater potential for therapeutic synergy with rituximab, which has a long half-life. We pooled the results of 3 prospective phase 2 trials evaluating rituximab in combination with 96-hour infusion of cyclophosphamide (187.5-200 mg\/m2 per day), doxorubicin (12.5 mg\/m2 per day), and etoposide (60 mg\/m2 per day) (R-CDE) plus granulocyte\u2013colony-stimulating factor (G-CSF) in 74 patients with HIV-associated, B-cell non-Hodgkin lymphoma, of whom 56 (76%) patients received concurrent highly active antiretroviral therapy (HAART). The complete remission (CR) rate was 70% (95% confidence interval [CI], 59%-81%), and the estimated 2-year failure-free survival and overall survival rates were 59% (95% CI, 47%-71%) and 64% (95% CI, 52%-76%), respectively. Ten (14%) patients had opportunistic infections during or within 3 months of the end of R-CDE, and 17 (23%) patients developed nonopportunistic infections after that time. Six (8%) patients died because of infection; 2 (3%) of those infections were bacterial sepsis during R-CDE, and 4 (5%) were opportunistic infections that occurred between 2 and 8 months after the completion of R-CDE. R-CDE produced a 70% CR rate and a 59% 2-year failure-free survival rate in patients with HIV-associated lymphoma. Consistent with other reports, adding rituximab to cytotoxic therapy in this population may increase the risk for life-threatening infection. Further studies evaluating rituximab in combination with infusional chemotherapy are warranted, but caution is advised.<\/jats:p>","DOI":"10.1182\/blood-2004-08-3300","type":"journal-article","created":{"date-parts":[[2004,11,18]],"date-time":"2004-11-18T20:14:16Z","timestamp":1100808856000},"page":"1891-1897","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":161,"title":["Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials"],"prefix":"10.1182","volume":"105","author":[{"given":"Michele","family":"Spina","sequence":"first","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Jaeger","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Talamini","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Simonelli","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Michieli","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Nigra","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin C.","family":"Rieger","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Vaccher","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Tirelli","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223160550200_REF1","doi-asserted-by":"crossref","unstructured":"Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338: 853-860.","DOI":"10.1056\/NEJM199803263381301"},{"key":"2020021223160550200_REF2","doi-asserted-by":"crossref","unstructured":"Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352: 1725-1730.","DOI":"10.1016\/S0140-6736(98)03201-2"},{"key":"2020021223160550200_REF3","doi-asserted-by":"crossref","unstructured":"Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992;80: 8-20.","DOI":"10.1182\/blood.V80.1.8.8"},{"key":"2020021223160550200_REF4","doi-asserted-by":"crossref","unstructured":"Kaplan LD, Strauss DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336: 1641-1648.","DOI":"10.1056\/NEJM199706053362304"},{"key":"2020021223160550200_REF5","doi-asserted-by":"crossref","unstructured":"Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy: French-Italian Cooperative Group. Am J Med. 1993;95: 188-196.","DOI":"10.1016\/0002-9343(93)90259-R"},{"key":"2020021223160550200_REF6","doi-asserted-by":"crossref","unstructured":"Gisselbrecht C, Spina M, Gabarre J, et al. Therapy of HIV-related non-Hodgkin's lymphoma: a European multicentric randomized study in patients stratified according to their prognostic factors: preliminary results [abstract]. J Acquir Immune Defic Syndr. 1997;14: A53. Abstract 149.","DOI":"10.1097\/00042560-199704010-00191"},{"key":"2020021223160550200_REF7","doi-asserted-by":"crossref","unstructured":"Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 2001;98: 2339-2344.","DOI":"10.1097\/00002030-200108170-00005"},{"key":"2020021223160550200_","doi-asserted-by":"crossref","unstructured":"Ge\u0301rard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Synd Hum Retrovirol. 2002;30: 478-484.","DOI":"10.1097\/00126334-200208150-00003"},{"key":"2020021223160550200_REF9","doi-asserted-by":"crossref","unstructured":"Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin's lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;37: 1556-1564.","DOI":"10.1086\/379517"},{"key":"2020021223160550200_REF10","doi-asserted-by":"crossref","unstructured":"Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142\u2014Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor: National Institute of Allergy and Infectious Diseases. J Clin Oncol. 1998;16: 3601-3606.","DOI":"10.1200\/JCO.1998.16.11.3601"},{"key":"2020021223160550200_REF11","doi-asserted-by":"crossref","unstructured":"Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol. 2004; 22: 1491-1500.","DOI":"10.1200\/JCO.2004.08.195"},{"key":"2020021223160550200_REF12","doi-asserted-by":"crossref","unstructured":"Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule dependent effect favoring infusional administration of chemotherapy. J Clin Oncol. 1993;11: 1071-1079.","DOI":"10.1200\/JCO.1993.11.6.1071"},{"key":"2020021223160550200_REF13","doi-asserted-by":"crossref","unstructured":"Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I\u2013related non-Hodgkin's lymphoma: a highly active regimen. Blood. 1993; 81: 2810-2815.","DOI":"10.1182\/blood.V81.10.2810.2810"},{"key":"2020021223160550200_REF14","unstructured":"Coiffer B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92: 1927-1932."},{"key":"2020021223160550200_REF15","doi-asserted-by":"crossref","unstructured":"Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19: 389-397.","DOI":"10.1200\/JCO.2001.19.2.389"},{"key":"2020021223160550200_REF16","doi-asserted-by":"crossref","unstructured":"Demiden A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12: 177-186.","DOI":"10.1089\/cbr.1997.12.177"},{"key":"2020021223160550200_REF17","doi-asserted-by":"crossref","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15: 3266-3274.","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"2020021223160550200_REF18","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13: 193-207.","DOI":"10.1038\/modpathol.3880035"},{"key":"2020021223160550200_REF19","doi-asserted-by":"crossref","unstructured":"Spina M, Sparano JA, Jaegaer U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS. 2003;17: 137-138.","DOI":"10.1097\/00002030-200301030-00024"},{"key":"2020021223160550200_REF20","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on non-Hodgkin's Disease Classification. Cancer Res. 1971;31: 1860-1861."},{"key":"2020021223160550200_REF21","doi-asserted-by":"crossref","unstructured":"Miller AB, Hoogstragen B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47: 207-214.","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"2020021223160550200_REF22","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021223160550200_REF23","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50: 163-170."},{"key":"2020021223160550200_REF24","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc Br. 1972;34: 187-202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2020021223160550200_REF25","doi-asserted-by":"crossref","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive lymphoma. N Engl J Med. 1993;329: 987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"2020021223160550200_REF26","doi-asserted-by":"crossref","unstructured":"Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus\u2013associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001; 19: 2171-2178.","DOI":"10.1200\/JCO.2001.19.8.2171"},{"key":"2020021223160550200_REF27","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346: 235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"2020021223160550200_REF28","doi-asserted-by":"crossref","unstructured":"Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients &lt; 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without anti-CD20 antibody rituximab\u2014early stopping after the first interim analysis. Proc Am Soc Clin Oncol. 2004;23: 556. Abstract 6500.","DOI":"10.1200\/jco.2004.22.14_suppl.6500"},{"key":"2020021223160550200_REF29","unstructured":"Kaplan LD, Scadden DT. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS Malignancies Consortium Study 010. Proc Am Soc Clin Oncol. 2003;22: 564. Abstract 2268."},{"key":"2020021223160550200_REF30","doi-asserted-by":"crossref","unstructured":"Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy induced neutropenia. Blood. 2004;104: 2943-2946.","DOI":"10.1182\/blood-2004-05-1747"},{"key":"2020021223160550200_REF31","unstructured":"Boue F, Gabarre J, Gisselbrecht C, et al. CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma: results of an ANRS trial. Proc Am Soc Hematol. 2002;470. Abstract 1824."},{"key":"2020021223160550200_REF32","doi-asserted-by":"crossref","unstructured":"Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EP-OCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101: 4653-4659.","DOI":"10.1182\/blood-2002-11-3589"},{"key":"2020021223160550200_REF33","doi-asserted-by":"crossref","unstructured":"Wilson WH, Grossbard ML, Pitaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002; 99: 2685-2693.","DOI":"10.1182\/blood.V99.8.2685"},{"key":"2020021223160550200_REF34","doi-asserted-by":"crossref","unstructured":"Sparano JA, Weller E, Nazeer T, Habermann TM, Traynor, A, Cassileth P. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor prognosis intermediate- or high-grade non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002;100: 1634-1640.","DOI":"10.1182\/blood.V100.5.1634.h81702001634_1634_1640"},{"key":"2020021223160550200_REF35","doi-asserted-by":"crossref","unstructured":"Sparano JA, Wiernik PH, Hu X, et al. A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 1996;14: 3026-3035.","DOI":"10.1200\/JCO.1996.14.11.3026"},{"key":"2020021223160550200_REF36","unstructured":"AIDS-Associated Malignancies Clinical Trials Consortium. A randomized phase II trial of epoch given either concurrently or sequentially with rituximab in patients with intermediate- or high-grade HIV-associated B-cell Non-Hodgkin's lymphoma. Available at: http:\/\/www.amc.uab.edu\/034des.htm. Accessed December 4, 2004."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/5\/1891\/1707027\/zh800505001891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/5\/1891\/1707027\/zh800505001891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:16:21Z","timestamp":1581549381000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/5\/1891\/20291\/Rituximab-plus-infusional-cyclophosphamide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-08-3300","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,1]]}}}